Loading...

Genmab A/S

GNMSFā€¢PNK
Healthcare
Biotechnology
$255.25
$-16.57(-6.10%)
U.S. Market opens in 3h 21m

Genmab A/S (GNMSF) Stock Overview

Explore Genmab A/Sā€™s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap15.7B
P/E Ratio4.05
EPS (TTM)$15.36
ROE0.19%
Fundamental Analysis

AI Price Forecasts

1 Month$294.35
3 Months$260.47
1 Year Target$228.13

GNMSF Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GNMSF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 32.02, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $228.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 4.05 and a market capitalization of 15.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-6.10%
5-Day Change
-6.10%
1-Month Change
-4.47%
3-Month Change
-24.93%
6-Month Change
-9.84%
Year-to-Date (YTD) Change
-18.71%
1-Year Change
25.76%
3-Year Change
-37.55%
5-Year Change
-31.92%
All-Time (Max) Change
1536.22%

Contact Information

https://www.genmab.com
45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

2,638 Employees
IPO DateJan 5, 2010
CountryDK
Actively Trading

Frequently Asked Questions